{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:37:05Z","timestamp":1792089425160,"version":"4.4.0"},"reference-count":157,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China","award":["31871281"],"award-info":[{"award-number":["31871281"]}]},{"name":"National Natural Science Foundation of China","award":["2020XGKY12"],"award-info":[{"award-number":["2020XGKY12"]}]},{"name":"Scientific Research Foundation for Advanced Talents of Shanghai University of Traditional Chinese Medicine","award":["31871281"],"award-info":[{"award-number":["31871281"]}]},{"name":"Scientific Research Foundation for Advanced Talents of Shanghai University of Traditional Chinese Medicine","award":["2020XGKY12"],"award-info":[{"award-number":["2020XGKY12"]}]},{"name":"Shanghai Municipal Health Commission","award":["31871281"],"award-info":[{"award-number":["31871281"]}]},{"name":"Shanghai Municipal Health Commission","award":["2020XGKY12"],"award-info":[{"award-number":["2020XGKY12"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Viral DNA and RNA polymerases are two kinds of very important enzymes that synthesize the genetic materials of the virus itself, and they have become extremely favorable targets for the development of antiviral drugs because of their relatively conserved characteristics. There are many similarities in the structure and function of different viral polymerases, so inhibitors designed for a certain viral polymerase have acted as effective universal inhibitors on other types of viruses. The present review describes the development of classical antiviral drugs targeting polymerases, summarizes a variety of viral polymerase inhibitors from the perspective of chemically synthesized drugs and natural product drugs, describes novel approaches, and proposes promising development strategies for antiviral drugs.<\/jats:p>","DOI":"10.3390\/molecules27217370","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T09:01:42Z","timestamp":1667120502000},"page":"7370","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Progression of Antiviral Agents Targeting Viral Polymerases"],"prefix":"10.3390","volume":"27","author":[{"given":"Siqi","family":"Peng","sequence":"first","affiliation":[{"name":"Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengtao","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7472-996X","authenticated-orcid":false,"given":"Qingzhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-94-007-6552-8_1","article-title":"Introduction: The structural basis of virus function","volume":"68","author":"Mateu","year":"2013","journal-title":"Subcell. Biochem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.cell.2020.08.021","article-title":"Emerging Pandemic Diseases: How We Got to COVID-19","volume":"182","author":"Morens","year":"2020","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10096-003-1059-3","article-title":"Human health implications of avian influenza viruses and paramyxoviruses","volume":"23","author":"Capua","year":"2004","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved Antiviral Drugs over the Past 50 Years","volume":"29","author":"Li","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Richman, D.D., and Nathanson, N. (2016). Antiviral Therapy. Viral Pathogenesis, Elsevier Ltd.","DOI":"10.1016\/B978-0-12-800964-2.00020-3"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4254\/wjh.v8.i2.92","article-title":"Chronic hepatitis C: This and the new era of treatment","volume":"8","author":"Bertino","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Vardanyan, R., and Hruby, V. (2016). Antiviral Drugs. Synthesis of Best-Seller Drugs, Academic Press.","DOI":"10.1016\/B978-0-12-411492-0.00034-1"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Fenner, F., Bachmann, P.A., Gibbs, E.P.J., Murphy, F.A., Studdert, M.J., and White, D.O. (1987). Viral Replication. Veterinary Virology, Elsevier.","DOI":"10.1016\/B978-0-12-253055-5.50008-6"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","article-title":"Molecular biology of hepatitis B virus infection","volume":"479","author":"Seeger","year":"2015","journal-title":"Virology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cld.2007.08.002","article-title":"Molecular virology of hepatitis B virus for clinicians","volume":"11","author":"Block","year":"2007","journal-title":"Clin. Liver Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Qi, Y., Gao, Z., Xu, G., Peng, B., Liu, C., Yan, H., Yao, Q., Sun, G., Liu, Y., and Tang, D.J.P. (2016). DNA polymerase \u03ba is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005893"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4155\/fmc.15.19","article-title":"Recent advance of the hepatitis B virus inhibitors: A medicinal chemistry overview","volume":"7","author":"Jia","year":"2015","journal-title":"Future Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1038\/emi.2013.56","article-title":"Hepatitis B virus reverse transcriptase: Diverse functions as classical and emerging targets for antiviral intervention","volume":"2","author":"Jones","year":"2013","journal-title":"Emerg. Microbes Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"a021386","DOI":"10.1101\/cshperspect.a021386","article-title":"Hepadnavirus Genome Replication and Persistence","volume":"5","author":"Hu","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jhep.2016.02.009","article-title":"Attacking hepatitis B virus cccDNA\u2013The holy grail to hepatitis B cure","volume":"64","author":"Lucifora","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1046\/j.1440-1746.2000.0150121356.x","article-title":"Chronic hepatitis B virus infection in Asian countries","volume":"15","author":"Merican","year":"2000","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1128\/JVI.00582-13","article-title":"Sulfamoylbenzamide derivatives inhibit the assembly of hepatitis B virus nucleocapsids","volume":"87","author":"Campagna","year":"2013","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2014.04.005","article-title":"Nucleoside\/nucleotide analog inhibitors of hepatitis B virus polymerase: Mechanism of action and resistance","volume":"8","author":"Pacheco","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcv.2004.02.009","article-title":"Antiviral drugs in current clinical use","volume":"30","year":"2004","journal-title":"J. Clin. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.3748\/wjg.v16.i48.6145","article-title":"Pegylated interferon \u03b1-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B","volume":"16","author":"Chen","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.7326\/0003-4819-107-2-383","article-title":"Neurologic manifestations of infection with human immunodeficiency virus: Clinical features and pathogenesis","volume":"107","author":"Gabuzda","year":"1987","journal-title":"Ann. Intern. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3390\/biology1030521","article-title":"Inhibitors of HIV-1 reverse transcriptase\u2014Associated ribonuclease H activity","volume":"1","author":"Ilina","year":"2012","journal-title":"Biology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1006\/abbi.1999.1209","article-title":"HIV-1 reverse transcription: A brief overview focused on structure\u2013function relationships among molecules involved in initiation of the reaction","volume":"365","author":"Li","year":"1999","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11536","DOI":"10.1021\/bi960364x","article-title":"Biochemical analysis of catalytically crucial aspartate mutants of human immunodeficiency virus type 1 reverse transcriptase","volume":"35","author":"Kaushik","year":"1996","journal-title":"Biochemistry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"586401","DOI":"10.1155\/2012\/586401","article-title":"HIV-1 reverse transcriptase still remains a new drug target: Structure, function, classical inhibitors, and new inhibitors with innovative mechanisms of actions","volume":"2012","author":"Esposito","year":"2012","journal-title":"Mol. Biol. Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2174\/1570162043351093","article-title":"Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding","volume":"2","author":"Temiz","year":"2004","journal-title":"Curr. HIV Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"14410","DOI":"10.1073\/pnas.222366699","article-title":"Structure of HIV-2 reverse transcriptase at 2.35-\u00c5 resolution and the mechanism of resistance to non-nucleoside inhibitors","volume":"99","author":"Ren","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2006.11.018","article-title":"Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs)","volume":"352","author":"Hang","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/1742-4690-5-114","article-title":"Integrase and integration: Biochemical activities of HIV-1 integrase","volume":"5","author":"Delelis","year":"2008","journal-title":"Retrovirology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Li, G., and De Clercq, E. (2021). Overview of Antiviral Drug Discovery and Development: Viral Versus Host Targets. Antiviral Discovery for Highly Pathogenic Emerging Viruses, Royal Society of Chemistry.","DOI":"10.1039\/9781788016858-00001"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00042737-200105000-00001","article-title":"Hepatitis C virus infection: 10 years after the discovery of the virus","volume":"13","author":"Ramadori","year":"2001","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"De Francesco, R., Neddermann, P., Tomei, L., Steink\u00fchler, C., Gallinari, P., and Folgori, A. (2000). Biochemical and Immunologic Properties of the Nonstructural Proteins of the Hepatitis C Virus: Implications for Development of Antiviral Agents and Vaccines. Seminars in Liver Disease, Thieme Medical Publishers, Inc.","DOI":"10.1055\/s-2000-9504"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1128\/jvi.71.11.8416-8428.1997","article-title":"Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity","volume":"71","author":"Lohmann","year":"1997","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3390\/v2102169","article-title":"Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B","volume":"2","author":"Powdrill","year":"2010","journal-title":"Viruses"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1021\/jm201384j","article-title":"Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase","volume":"55","author":"Sofia","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Stefanik, M., Valdes, J.J., Ezebuo, F.C., Haviernik, J., Uzochukwu, I.C., Fojtikova, M., Salat, J., Eyer, L., and Ruzek, D. (2020). FDA-approved drugs efavirenz, tipranavir, and dasabuvir inhibit replication of multiple flaviviruses in vero cells. Microorganisms, 8.","DOI":"10.3390\/microorganisms8040599"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"15G.1.1","DOI":"10.1002\/9780471729259.mc15g01s29","article-title":"Influenza: Propagation, quantification, and storage","volume":"29","author":"Balish","year":"2013","journal-title":"Curr. Protoc. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Tellier, R., Li, Y., Cowling, B.J., and Tang, J.W. (2019). Recognition of aerosol transmission of infectious agents: A commentary. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-3707-y"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(09)61512-9","article-title":"Swine-origin influenza virus H1N1, seasonal influenza virus, and critical illness in children","volume":"374","author":"Lister","year":"2009","journal-title":"Lancet"},{"key":"ref_40","first-page":"3","article-title":"Properties of coronavirus and SARS-CoV-2","volume":"42","author":"Malik","year":"2020","journal-title":"Malays. J. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/09273948.2020.1738501","article-title":"Can the coronavirus disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals","volume":"28","author":"Seah","year":"2020","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_42","unstructured":"Guarner, J. (2020). Three Emerging Coronaviruses in Two Decades: The Story of SARS, MERS, and Now COVID-19, Oxford University Press."},{"key":"ref_43","first-page":"1141","article-title":"RNA-dependent RNA polymerase as a target for COVID-19 drug discovery","volume":"25","author":"Zhu","year":"2020","journal-title":"Adv. Sci. Drug Discov."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/s41467-019-10280-3","article-title":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors","volume":"10","author":"Kirchdoerfer","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Borbone, N., Piccialli, G., Roviello, G.N., and Oliviero, G. (2021). Nucleoside analogs and nucleoside precursors as drugs in the fight against SARS-CoV-2 and other coronaviruses. Molecules, 26.","DOI":"10.3390\/molecules26040986"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0074-7696(05)45006-8","article-title":"Interactions between virus proteins and host cell membranes during the viral life cycle","volume":"245","author":"Villanueva","year":"2005","journal-title":"Int. Rev. Cytol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4065\/mcp.2011.0309","article-title":"Antiviral drugs for viruses other than human immunodeficiency virus","volume":"86","author":"Razonable","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrmicro.2016.87","article-title":"Influenza virus RNA polymerase: Insights into the mechanisms of viral RNA synthesis","volume":"14","author":"Fodor","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1128\/jvi.61.7.2217-2224.1987","article-title":"Intracellular localization of the viral polymerase proteins in cells infected with influenza virus and cells expressing PB1 protein from cloned cDNA","volume":"61","author":"Akkina","year":"1987","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/j.1460-2075.1986.tb04506.x","article-title":"Nuclear location of all three influenza polymerase proteins and a nuclear signal in polymerase PB2","volume":"5","author":"Jones","year":"1986","journal-title":"EMBO J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0042-6822(87)90004-3","article-title":"Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses","volume":"160","author":"Smith","year":"1987","journal-title":"Virology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1128\/jvi.71.3.1850-1856.1997","article-title":"The NPI-1\/NPI-3 (karyopherin alpha) binding site on the influenza a virus nucleoprotein NP is a nonconventional nuclear localization signal","volume":"71","author":"Wang","year":"1997","journal-title":"J. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11013","DOI":"10.1074\/jbc.M112.392878","article-title":"Structural and functional characterization of K339Tsubstitution identified in the PB2 subunit cap-binding pocket of influenza A virus","volume":"288","author":"Liu","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_55","first-page":"3353","article-title":"An in vitro fluorescence based study of initiation of RNA synthesis by influenza B polymerase","volume":"45","author":"Reich","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1128\/JVI.00277-11","article-title":"Replication-coupled and host factor-mediated encapsidation of the influenza virus genome by viral nucleoprotein","volume":"85","author":"Kawaguchi","year":"2011","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/JVI.02300-08","article-title":"Detection and characterization of influenza A virus PA-PB2 interaction through a bimolecular fluorescence complementation assay","volume":"83","author":"Hemerka","year":"2009","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Dufrasne, F. (2021). Baloxavir Marboxil: An Original New Drug against Influenza. Pharmaceuticals, 15.","DOI":"10.3390\/ph15010028"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/INF.0000000000002747","article-title":"Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2)","volume":"39","author":"Baker","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.antiviral.2012.09.013","article-title":"Targeting the host or the virus: Current and novel concepts for antiviral approaches against influenza virus infection","volume":"96","author":"Lee","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_61","first-page":"9","article-title":"Xofluza (Baloxavir Marboxil) for the Treatment of Acute Uncomplicated Influenza","volume":"44","author":"Ng","year":"2019","journal-title":"Pharm. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","article-title":"Favipiravir: A new and emerging antiviral option in COVID-19","volume":"76","author":"Agrawal","year":"2020","journal-title":"Med. J. Armed Forces India"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"20587384211002621","DOI":"10.1177\/20587384211002621","article-title":"A review: Mechanism of action of antiviral drugs","volume":"35","author":"Kausar","year":"2021","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/AAC.44.4.859-866.2000","article-title":"Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: A comparison with ribavirin and demonstration of antiviral additivity with alpha interferon","volume":"44","author":"Markland","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13008-018-0038-0","article-title":"IMP\/GTP balance modulates cytoophidium assembly and IMPDH activity","volume":"13","author":"Keppeke","year":"2018","journal-title":"Cell Div."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.meegid.2014.12.022","article-title":"Recombination in viruses: Mechanisms, methods of study, and evolutionary consequences","volume":"30","author":"Arenas","year":"2015","journal-title":"Infect. Genet. Evol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"105035","DOI":"10.1016\/j.antiviral.2021.105035","article-title":"Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir","volume":"188","author":"Patel","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"ofz137","DOI":"10.1093\/ofid\/ofz137","article-title":"Clinical Development of Therapeutic Agents for Hospitalized Patients with Influenza: Challenges and Innovations","volume":"6","author":"King","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1080\/07391102.2021.1875886","article-title":"RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2","volume":"40","author":"Mishra","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cbpa.2018.06.004","article-title":"Inhibitors of protein-protein interactions (PPIs): An analysis of scaffold choices and buried surface area","volume":"44","author":"Ran","year":"2018","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"10118","DOI":"10.1021\/jm401560v","article-title":"Structural Investigation of Cycloheptathiophene-3-carboxamide Derivatives Targeting Influenza Virus Polymerase Assembly","volume":"56","author":"Massari","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1874091X00903010039","article-title":"The Hepatitis C Virus NS5A Stimulates NS5B During In Vitro RNA Synthesis in a Template Specific Manner","volume":"3","author":"Quezada","year":"2009","journal-title":"Open Biochem. J."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Picarazzi, F., Vicenti, I., Saladini, F., Zazzi, M., and Mori, M. (2020). Targeting the RdRp of emerging RNA viruses: The structure-based drug design challenge. Molecules, 25.","DOI":"10.3390\/molecules25235695"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.1128\/JVI.79.14.8687-8697.2005","article-title":"Stimulation of hepatitis C virus (HCV) nonstructural protein 3 (NS3) helicase activity by the NS3 protease domain and by HCV RNA-dependent RNA polymerase","volume":"79","author":"Zhang","year":"2005","journal-title":"J. Virol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cld.2011.05.003","article-title":"The HCV NS5B nucleoside and non-nucleoside inhibitors","volume":"15","author":"Membreno","year":"2011","journal-title":"Clin. Liver Dis."},{"key":"ref_78","first-page":"218","article-title":"Mechanism of action of ribavirin in the treatment of chronic hepatitis C","volume":"3","author":"Te","year":"2007","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.antiviral.2017.04.005","article-title":"Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs","volume":"143","author":"Jin","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.bpj.2015.03.005","article-title":"Allosteric inhibitors have distinct effects, but also common modes of action, in the HCV polymerase","volume":"108","author":"Davis","year":"2015","journal-title":"Biophys. J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"13904","DOI":"10.1073\/pnas.1506405112","article-title":"Interrogating the activities of conformational deformed enzyme by single-molecule fluorescence-magnetic tweezers microscopy","volume":"112","author":"Guo","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/1756283X09336045","article-title":"Therapeutic implications of hepatitis C virus resistance to antiviral drugs","volume":"2","author":"Pawlotsky","year":"2009","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6095","DOI":"10.1128\/JVI.75.13.6095-6106.2001","article-title":"Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response","volume":"75","author":"Polyak","year":"2001","journal-title":"J. Virol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"Scheel","year":"2013","journal-title":"Nat. Med."},{"key":"ref_85","first-page":"41","article-title":"Approaches to hepatitis C treatment and cure using NS5A inhibitors","volume":"7","author":"Kohler","year":"2014","journal-title":"Infect. Drug Resist."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/17474124.2016.1116937","article-title":"Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection","volume":"10","author":"Sundaram","year":"2016","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jmb.2008.10.071","article-title":"Structure and function of HIV-1 reverse transcriptase: Molecular mechanisms of polymerization and inhibition","volume":"385","author":"Sarafianos","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_88","first-page":"55","article-title":"Replication and Expression Strategies of Viruses","volume":"2018","author":"Rampersad","year":"2018","journal-title":"Viruses"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.virusres.2007.12.007","article-title":"RNase H activity: Structure, specificity, and function in reverse transcription","volume":"134","author":"Schultz","year":"2008","journal-title":"Virus Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1128\/MMBR.00065-15","article-title":"HIV genome-wide protein associations: A review of 30 years of research","volume":"80","author":"Li","year":"2016","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/14728214.2018.1474202","article-title":"Emerging reverse transcriptase inhibitors for HIV-1 infection","volume":"23","author":"Rai","year":"2018","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_92","first-page":"411","article-title":"Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics","volume":"15","author":"Holec","year":"2017","journal-title":"Curr. HIV Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"14621","DOI":"10.1021\/acsomega.1c01742","article-title":"HIV Reverse Transcriptase Pre-Steady-State Kinetic Analysis of Chain Terminators and Translocation Inhibitors Reveals Interactions between Magnesium and Nucleotide 3\u2032-OH","volume":"6","author":"Dilmore","year":"2021","journal-title":"ACS Omega"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1128\/JVI.77.10.5685-5693.2003","article-title":"A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation","volume":"77","author":"MacInnes","year":"2003","journal-title":"J. Virol."},{"key":"ref_95","first-page":"153","article-title":"The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection","volume":"38","year":"1998","journal-title":"Antivir. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e101801","DOI":"10.15252\/embj.2019101801","article-title":"DNA damage kinase signaling: Checkpoint and repair at 30 years","volume":"38","author":"Lanz","year":"2019","journal-title":"Embo J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"18567","DOI":"10.7448\/IAS.16.1.18567","article-title":"Non-nucleoside reverse transcriptase inhibitors: A review on pharmacokinetics, pharmacodynamics, safety and tolerability","volume":"16","author":"Usach","year":"2013","journal-title":"J Int. AIDS Soc."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0014-5793(01)02945-3","article-title":"HIV-1 reverse transcriptase and integrase enzymes physically interact and inhibit each other","volume":"507","author":"Tasara","year":"2001","journal-title":"FEBS Lett."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications","volume":"203","author":"Blanco","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2217\/fvl.12.56","article-title":"The molecular biology of HIV integrase","volume":"7","author":"Craigie","year":"2012","journal-title":"Future Virol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e00611","DOI":"10.1128\/AAC.00611-20","article-title":"HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants","volume":"64","author":"Smith","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","article-title":"Structure of replicating SARS-CoV-2 polymerase","volume":"584","author":"Hillen","year":"2020","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"104793","DOI":"10.1016\/j.antiviral.2020.104793","article-title":"Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites","volume":"178","author":"Shannon","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.coviro.2021.03.010","article-title":"Structure and function of SARS-CoV-2 polymerase","volume":"48","author":"Hillen","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"113201","DOI":"10.1016\/j.ejmech.2021.113201","article-title":"RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic","volume":"213","author":"Tian","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","article-title":"Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19","volume":"6","author":"Eastman","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/bs.enz.2021.07.002","article-title":"Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs","volume":"49","author":"Maheden","year":"2021","journal-title":"Enzymes"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"11022","DOI":"10.1038\/s41598-021-90551-6","article-title":"The efficacy and safety of Favipiravir in treatment of COVID-19: A systematic review and meta-analysis of clinical trials","volume":"11","author":"Hassanipour","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4269\/ajtmh.21-0200","article-title":"COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact","volume":"105","author":"Maxwell","year":"2021","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_110","first-page":"e00900","article-title":"Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle","volume":"64","author":"Thaler","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41594-021-00570-0","article-title":"Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin","volume":"28","author":"Yin","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Venkataraman, S., Prasad, B., and Selvarajan, R. (2018). RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution. Viruses, 10.","DOI":"10.3390\/v10020076"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-021-01146-7","article-title":"Protein degradation technology: A strategic paradigm shift in drug discovery","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"8880","DOI":"10.1021\/acs.jmedchem.9b01927","article-title":"How we think about targeting RNA with small molecules","volume":"63","author":"Costales","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs)\u2014Past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/s41422-021-00533-6","article-title":"Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently","volume":"31","author":"Yang","year":"2021","journal-title":"Cell Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mrd.20406","article-title":"Targeted suppression of E-cadherin gene expression in bovine preimplantation embryo by RNA interference technology using double-stranded RNA","volume":"73","author":"Nganvongpanit","year":"2006","journal-title":"Mol Reprod Dev."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/cpdd.318","article-title":"Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers","volume":"6","author":"Schluep","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/gutjnl-2020-323445","article-title":"Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment","volume":"71","author":"Yuen","year":"2022","journal-title":"Gut"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"S688","DOI":"10.1016\/S0168-8278(17)31850-0","article-title":"HBcrAg, HBV-RNA declines in a phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg-positive and negative virally suppressed subjects with hepatitis B","volume":"66","author":"Agarwal","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/liv.14364","article-title":"Can we cure hepatitis B virus with novel directrect Symonds","volume":"40","author":"Martinez","year":"2020","journal-title":"Liver Int."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1021\/acsinfecdis.0c00638","article-title":"HBsAg, subviral particles, and their clearance in establishing a functional cure of chronic hepatitis B virus infection","volume":"7","author":"Vaillant","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.antiviral.2017.11.015","article-title":"The diverse functions of the hepatitis B core\/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals","volume":"149","author":"Diab","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.virusres.2007.12.024","article-title":"Hepatitis B viruses: Reverse transcription a different way","volume":"134","author":"Nassal","year":"2008","journal-title":"Virus Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1128\/JVI.03545-14","article-title":"The interface between hepatitis B virus capsid proteins affects self-assembly, pregenomic RNA packaging, and reverse transcription","volume":"89","author":"Tan","year":"2015","journal-title":"J. Virol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1128\/JVI.03058-15","article-title":"Hepatitis B virus capsids have diverse structural responses to small-molecule ligands bound to the heteroaryldihydropyrimidine pocket","volume":"90","author":"Venkatakrishnan","year":"2016","journal-title":"J. Virol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/14728222.2017.1397134","article-title":"Hepatitis B core protein as a therapeutic target","volume":"21","author":"Mak","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_131","unstructured":"Schlicksup, C. (2020). Hepatitis B Virus Capsid Protein as an Antiviral Target, Indiana University."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/jmr.801","article-title":"BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly","volume":"19","author":"Stray","year":"2006","journal-title":"J. Mol. Recognit. JMR"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"8134","DOI":"10.1021\/acs.jmedchem.0c00346","article-title":"Discovery of phthalazinone derivatives as novel hepatitis B virus capsid inhibitors","volume":"63","author":"Chen","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_134","first-page":"557","article-title":"Naturally derived anti-HIV agents","volume":"19","author":"Asres","year":"2005","journal-title":"Phytother. Res. Int. J. Devoted Pharmacol. Toxicol. Eval. Nat. Prod. Deriv."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2174\/157016206777709393","article-title":"Coumarins as inhibitors of HIV reverse transcriptase","volume":"4","author":"Kostova","year":"2006","journal-title":"Curr. HIV Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/cbic.201600592","article-title":"Natural Product Kuwanon-L Inhibits HIV-1 Replication through Multiple Target Binding","volume":"18","author":"Martini","year":"2017","journal-title":"ChemBioChem"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1021\/acs.jnatprod.7b00004","article-title":"Potent inhibitor of drug-resistant HIV-1 strains identified from the medicinal plant Justicia gendarussa","volume":"80","author":"Zhang","year":"2017","journal-title":"J. Nat. Prod."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1021\/jm00093a004","article-title":"HIV inhibitory natural products. Part 7. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum","volume":"35","author":"Kashman","year":"1992","journal-title":"J. Med. Chem."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jep.2012.09.036","article-title":"Identification and evaluation of anti hepatitis C virus phytochemicals from Eclipta alba","volume":"144","author":"Manvar","year":"2012","journal-title":"J. Ethnopharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"10465","DOI":"10.3390\/molecules180910465","article-title":"Biological activities and phytochemicals of Swietenia macrophylla King","volume":"18","author":"Moghadamtousi","year":"2013","journal-title":"Molecules"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"22796","DOI":"10.1038\/s41598-021-02266-3","article-title":"An integrated method for optimized identification of effective natural inhibitors against SARS-CoV-2 3CLpro","volume":"11","author":"Liao","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.3390\/v7102876","article-title":"HCV drug resistance challenges in Japan: The role of pre-existing variants and emerging resistant strains in direct acting antiviral therapy","volume":"7","author":"Chayama","year":"2015","journal-title":"Viruses"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1021\/acs.chemrev.1c00118","article-title":"Introduction: Drug Resistance","volume":"121","author":"Schiffer","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Pardo, J., Shukla, A.M., Chamarthi, G., and Gupte, A. (2020). The journey of remdesivir: From Ebola to COVID-19. Drugs Context, 9.","DOI":"10.7573\/dic.2020-4-14"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2174\/138161206776361156","article-title":"Antiviral therapy targeting viral polymerase","volume":"12","author":"Tsai","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1021\/jm701260b","article-title":"Prodrugs of phosphates and phosphonates","volume":"51","author":"Hecker","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/(SICI)1520-6017(200006)89:6<781::AID-JPS10>3.0.CO;2-7","article-title":"Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2","volume":"89","author":"Sugawara","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/jps.21047","article-title":"Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting","volume":"97","author":"Li","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrd703","article-title":"Strategies in the design of antiviral drugs","volume":"1","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/metabo2020303","article-title":"A historical overview of natural products in drug discovery","volume":"2","author":"Dias","year":"2012","journal-title":"Metabolites"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1039\/D0CS01118E","article-title":"Antiviral drug discovery: Preparing for the next pandemic","volume":"50","author":"Adamson","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1021\/acs.jnatprod.0c00968","article-title":"Natural products with potential to treat RNA virus pathogens including SARS-CoV-2","volume":"84","author":"Christy","year":"2020","journal-title":"J. Nat. Prod."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Musarra-Pizzo, M., Pennisi, R., Ben-Amor, I., Mandalari, G., and Sciortino, M.T. (2021). Antiviral activity exerted by natural products against human viruses. Viruses, 13.","DOI":"10.3390\/v13050828"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1743-422X-3-68","article-title":"Natural products that reduce rotavirus infectivity identified by a cell-based moderate-throughput screening assay","volume":"3","author":"Shaneyfelt","year":"2006","journal-title":"Virol. J."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1021\/acs.jmedchem.6b00738","article-title":"Design, synthesis, and evaluation of thiophene [3, 2-d] pyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles","volume":"59","author":"Kang","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.apsb.2015.09.008","article-title":"Direct anti-HCV agents","volume":"6","author":"Zhang","year":"2016","journal-title":"Acta Pharm. Sin. B"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/21\/7370\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:05:51Z","timestamp":1760144751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/21\/7370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":157,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["molecules27217370"],"URL":"https:\/\/doi.org\/10.3390\/molecules27217370","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]}}}